Gastroenterology · Acupuncture
This clinical trial explores a non-pharmacological approach to treating constipation, which could disrupt the current market for laxatives and other bowel motility treatments. If successful, it may lead to a shift in treatment paradigms, prompting pharma companies to reassess their strategies in gastrointestinal therapies.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/26/2026, 12:31:36 AM
Assessment confidence: 66% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
This clinical trial explores a non-pharmacological approach to treating constipation, which could disrupt the current market for laxatives and other bowel motility treatments. If successful, it may lead to a shift in treatment paradigms, prompting pharma companies to reassess their strategies in gastrointestinal therapies. Assessment grounded in 18 ranked evidence items (9 high-relevance).
Pharma companies focusing on gastrointestinal therapies should monitor this study closely as it may shift treatment paradigms and patient preferences. The strongest clinical anchor is Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects (ClinicalTrials.gov), moderate corpus alignment. In Gastroenterology · Acupuncture, 0 regulatory and 4 competitive items passed relevance filtering for laxative manufacturers.
The most relevant competitive pressure comes from Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. If successful, this study could provide a non-pharmacological alternative for treating constipation, impacting the market for laxatives and other bowel motility treatments.
Regulatory outlook for laxative manufacturers is limited by sparse ingested precedent data.
No evidence in this category.
Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View sourceThorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMechanical Bowel Prep Randomized Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Impact of Laser Acupuncture on Type 2 Diabetes
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceStudy of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMerck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Study on Air Pollution's Impact on Cystic Fibrosis Severity in Hispanic Children
Humanexa Signalsmedium relevance
Moderate corpus alignment
UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceImpact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceSafety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceWrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceElevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourceDo subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThis clinical trial explores a non-pharmacological approach to treating constipation, which could disrupt the current market for laxatives and other bowel motility treatments. If successful, it may lead to a shift in treatment paradigms, prompting pharma companies to reassess their strategies in gastrointestinal therapies.
The introduction of effective acupuncture-based therapies could reduce market share for traditional laxative products, impacting revenue streams for companies in this sector.
As this study is exploratory in nature, it is unlikely to have immediate regulatory implications unless it leads to new product development.
Results from the trial regarding changes in bowel motility and any subsequent interest from pharmaceutical companies in acupuncture-based therapies.
Track for follow-up milestones; no immediate action required.